aibio
Distress ·
LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%
The VIZZ maker targets approximately $70 million to $75 million in 2027 operating expenses, and CEO Eef Schimmelpennink will step down December 1, 2026.
LENZ LENZ Therapeutics, Inc.
LENZ Therapeutics (LENZ) news LENZ offering news
Latest LENZ Therapeutics news
- Financings
LENZ Therapeutics sells 1,748,634 shares at $45.75 in $80,000,000 block trade
The sale to a single investor was made under the company's at-the-market agreement with TD Securities (USA) LLC. LENZ reported the 1,748,634 shares sold at $45.75 in an 8-K filed October 8, 2025.
What LENZ Therapeutics does
LENZ Therapeutics is a commercial pharmaceutical company focused on developing and commercializing innovative therapies to improve vision. Its commercial product is VIZZ (aceclidine ophthalmic solution) 1.44%, formerly known as LNZ100. The FDA approved VIZZ on July 31, 2025 as the first and only FDA-approved aceclidine-based eye drop. It is a once-daily eye drop developed to restore clear near vision for up to 10 hours. The product is powered by aceclidine, which the company describes as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation. The company says it commercially launched VIZZ in the United States. Professional product sample distribution by the sales force to optometrists and ophthalmologists, and commercial shipments through an e-pharmacy partner, were initiated in October 2025. The company says it continues to establish licensing and distribution partnerships internationally to provide access to VIZZ globally. Its stated goal is to commercialize VIZZ successfully and become the category leader, and it says it has assembled an executive team with extensive clinical and commercial experience to execute that goal.
| Product or program | What it is | Stage |
|---|---|---|
| VIZZ (aceclidine ophthalmic solution 1.44%) | Aceclidine eye drop for vision improvement | FDA approved July 31, 2025 |
LENZ Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $19.1 million | $0 |
| Research and development | $18.7 million | $29.8 million |
| Net income (loss) | -$82.1 million | -$49.8 million |
| Cash from operations | -$69.2 million | -$59.4 million |
| Cash and equivalents | $25.2 million | $20.2 million |
Questions about LENZ Therapeutics
Has LENZ Therapeutics raised money recently?
Our latest story on this, dated Oct 8, 2025: "LENZ Therapeutics sells 1,748,634 shares at $45.75 in $80,000,000 block trade". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of LENZ Therapeutics?
LENZ Therapeutics, Inc. trades under the ticker LENZ on NASDAQ.
Where is LENZ Therapeutics listed?
LENZ Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of LENZ Therapeutics?
The SEC Central Index Key (CIK) for LENZ Therapeutics, Inc. is 1815776. Its filings are on SEC EDGAR.
How many shares does LENZ Therapeutics have outstanding?
31,420,343 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-11.
Which country or territory is LENZ Therapeutics listed under?
Our directory records LENZ Therapeutics, Inc. under United States.
What does LENZ Therapeutics do?
Our directory classifies LENZ Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of LENZ Therapeutics?
The ISIN recorded for LENZ Therapeutics, Inc. is US52635N1037.
Does aibio.space cover LENZ Therapeutics?
aibio.space lists LENZ Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is LENZ Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What does LENZ Therapeutics develop?
LENZ Therapeutics is a commercial pharmaceutical company focused on developing and commercializing innovative therapies to improve vision. Its commercial product is VIZZ (aceclidine ophthalmic solution) 1.44%, formerly known as LNZ100.
What is VIZZ (aceclidine ophthalmic solution 1.44%) from LENZ Therapeutics?
VIZZ (aceclidine ophthalmic solution 1.44%): Aceclidine eye drop for vision improvement Stage: FDA approved July 31, 2025.
What was LENZ Therapeutics's revenue last year?
$19.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is LENZ Therapeutics profitable?
LENZ Therapeutics, Inc. reported a net loss of $82.1 million for the fiscal year ended Dec 31, 2025, and used $69.2 million of cash in operations, per its annual report to the SEC.
How much does LENZ Therapeutics spend on research and development?
$18.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
Investor discussion: LENZ Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
SEC filings and registration
- SEC name
- LENZ Therapeutics, Inc.
- CIK
- 1815776
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- LENZ (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Business address
- 201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH, CA, 92075
- Phone
- 858-925-7000
- Shares outstanding
- 31,420,343 as of 2026-08-05 (10-Q filed 2026-08-11)
- Former names
- Graphite Bio, Inc.
Recent filings
Listing details
- Company
- LENZ Therapeutics, Inc.
- Ticker
- LENZ
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US52635N1037
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction